SAFETY DATA SHEET

Orbifloxacin Solid Formulation

Section 1: Identification

Product name : Orbifloxacin Solid Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand
Telephone : 908-740-4000
Emergency telephone number : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com
Telefax : 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

Section 2: Hazard identification

GHS Classification
Reproductive toxicity : Category 2

GHS label elements
Hazard pictograms :

Signal word : Warning
Hazard statements : H361d Suspected of damaging the unborn child.
Precautionary statements :
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P281 Use personal protective equipment as required.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/attention.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste
disposal plant.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&lt; 10</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Suspected of damaging the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders:
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician:
Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during fire-
Avoid generating dust; fine dust dispersed in air in sufficient
fighting concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Nitrogen oxides (NOx)
- Metal oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
  - Use water spray to cool unopened containers.
  - Remove undamaged containers from fire area if it is safe to do so.
  - Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

**Section 6: Accidental release measures**

<table>
<thead>
<tr>
<th>Personal precautions, protective equipment and emergency procedures</th>
<th>Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental precautions</td>
<td>Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.</td>
</tr>
<tr>
<td>Methods and materials for containment and cleaning up</td>
<td>Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</td>
</tr>
</tbody>
</table>

**Section 7: Handling and storage**

<table>
<thead>
<tr>
<th>Technical measures</th>
<th>Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local/Total ventilation Advice on safe handling</td>
<td>Use only with adequate ventilation. Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin.</td>
</tr>
</tbody>
</table>
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orbifloxacin</td>
<td>113617-63-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>WES-TWA</td>
<td>10 mg/m³</td>
<td>NZ OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures:
Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type
Particulates type
Hand protection
   Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
   Water solubility : No data available

Partition coefficient: n-
Section 10: Stability and reactivity

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:

Orbifloxacin:
Acute oral toxicity: LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Mouse): > 2,000 mg/kg
Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration):
- LD50 (Rat): > 200 mg/kg
  Application Route: Intramuscular
- LD50 (Mouse): 500 mg/kg
  Application Route: Intramuscular
- LD50 (Rat): 233 mg/kg
  Application Route: Intravenous
- LD50 (Mouse): 250 mg/kg
  Application Route: Intravenous

Magnesium stearate:
- Acute oral toxicity:
  - LD50 (Rat): > 2,000 mg/kg
    Method: OECD Test Guideline 423
    Assessment: The substance or mixture has no acute oral toxicity
    Remarks: Based on data from similar materials
- Acute dermal toxicity:
  - LD50 (Rabbit): > 2,000 mg/kg
    Remarks: Based on data from similar materials

Skin corrosion/irritation
Not classified based on available information.

Components:

Orbifloxacin:
- Species: Rabbit
- Method: Draize Test
- Result: No skin irritation

Magnesium stearate:
- Species: Rabbit
- Result: No skin irritation
- Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Orbifloxacin:
- Species: Rabbit
- Result: Mild eye irritation
- Method: Draize Test

Magnesium stearate:
- Species: Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Orbifloxacin:
Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Magnesium stearate:
Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Orbifloxacin:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

**Magnesium stearate:**
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Orbifloxacin:**
Species: Rat
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 2 Years
NOAEL: 200 mg/kg body weight
Result: negative

**Reproductive toxicity**
Suspected of damaging the unborn child.

**Components:**

**Orbifloxacin:**
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain

Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

**Magnesium stearate:**

Effects on fertility: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
Not classified based on available information.

**Repeated dose toxicity**

**Components:**

**Orbifloxacin:**
Species: Rat
NOAEL: 20 mg/kg
<table>
<thead>
<tr>
<th>LOAEL</th>
<th>80 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Testis, Liver, Kidney, spleen</td>
</tr>
</tbody>
</table>

Species : Mouse  
NOAEL : 80 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 3 Months  

Species : Juvenile dog  
NOAEL : 50 mg/kg  
LOAEL : 250 mg/kg  
Application Route : Oral  
Exposure time : 14 Days  
Target Organs : Heart, Bone  
Symptoms : Gastrointestinal disturbance  
Remarks : mortality observed  

Species : Juvenile dog  
NOAEL : 2 mg/kg  
LOAEL : 3 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Bone  
Remarks : No significant adverse effects were reported  

Species : Dog  
NOAEL : 37.5 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  

Species : Cat  
NOAEL : 7.5 mg/kg  
LOAEL : 22.5 mg/kg  
Application Route : Oral  
Exposure time : 1 Months  
Symptoms : Gastrointestinal disturbance  

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials  

Aspiration toxicity  
Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:
Ingestion
Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

Section 12: Ecological information

Ecotoxicity

Components:
Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility
NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:
Magnesium stearate:
Biodegradability: Result: Not biodegradable
Remarks: Based on data from similar materials
Bioaccumulative potential

Components:

Magnesium stearate:
Partition coefficient: n-octanol/water: log Pow: > 4

Mobility in soil
No data available

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

**Section 16: Other information**

**Further information**

Sources of key data used to compile the Safety Data Sheet:


Date format:

- dd.mm.yyyy

**Full text of other abbreviations**

- **ACGIH / TWA**: USA. ACGIH Threshold Limit Values (TLV)
- **NZ OEL / WES-TWA**: New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

- **ACGIH / TWA**: 8-hour, time-weighted average
- **NZ OEL / WES-TWA**: Workplace Exposure Standard - Time Weighted average

**Abbreviations**

- **AICIC**: Australian Inventory of Industrial Chemicals; **ANTT**: National Agency for Transport by Land of Brazil; **ASTM**: American Society for the Testing of Materials; **bw**: Body weight; **CMR**: Carcinogen, Mutagen or Reproductive Toxicant; **DIN**: Standard of the German Institute for Standardisation; **DSL**: Domestic Substances List (Canada); **ECx**: Concentration associated with x% response; **ELx**: Loading rate associated with x% response; **EmS**: Emergency Schedule; **ENCx**: Existing and New Chemical Substances (Japan); **ErCx**: Concentration associated with x% growth rate response; **ERG**: Emergency Response Guide; **GHS**: Globally Harmonized System; **GLP**: Good Laboratory Practice; **IC50**: Half maximal inhibitory concentration; **ICAO**: International Civil Aviation Organization; **IECSC**: Inventory of Existing Chemical Substances in China; **IMDG**: International Maritime Dangerous Goods; **IMO**: International Maritime Organization; **ISHL**: Industrial Safety and Health Law (Japan); **ISO**: International Organisation for Standardization; **KECI**: Korea Existing Chemicals Inventory; **LC50**: Lethal Concentration to 50% of a test population; **LD50**: Lethal Dose to 50% of a test population (Median Lethal Dose); **MARPOL**: International Convention for the Prevention of Pollution from Ships; **n.o.s.**: Not Otherwise Specified; **Nch**: Chilean Norm; **NO(A)EC**: No Observed (Adverse) Effect Concentration; **NO(A)EL**: No Observed (Adverse) Effect Level; **NOELR**: No Observable Effect Loading Rate; **NOM**: Official Mexican Norm; **NTP**: National Toxicology Program; **NZIoC**: New Zealand Inventory of Chemicals; **OECD**: Organization for Economic Co-operation and Development; **OPPTS**: Office of Chemical Safety and Pollution Prevention; **PBT**: Persistent, Bioaccumulative and Toxic substance; **PICCS**: Philippines Inventory of Chemicals and Chemical Substances; **(Q)SAR**: (Quantitative) Structure Activity Relationship; **REACH**: Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; **SADT**: Self-Accelerating Decomposition Temperature; **SDS**: Safety Data Sheet; **TCSI**: Taiwan Chemical Substance Inventory; **TDG**: Trans-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.